Valuation : Perspective Therapeutics, Inc.

Market Cap 357M 307M 289M 264M 493M 33.76B 495M 3.43B 1.32B 17.3B 1.34B 1.31B 55.08B P/E 2026 *
-3.13x
P/E 2027 * -2.97x
Enterprise Value 191M 164M 154M 141M 263M 18.02B 264M 1.83B 707M 9.24B 716M 701M 29.4B EV / Sales 2026 *
569x
EV / Sales 2027 * 319x
Free-Float
89.27%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week+0.64%
Current month-0.95%
1 month+5.39%
3 months+3.30%
6 months-37.02%
Current year+13.82%
1 week 3.02
Extreme 3.025
3.24
1 month 2.94
Extreme 2.935
3.56
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 2023-02-04
Director of Finance/CFO 59 2025-09-03
Chief Tech/Sci/R&D Officer - 2026-07-07
Director TitleAgeSince
Director/Board Member 54 2023-02-04
Chairman 63 2023-02-02
Director/Board Member 60 2023-02-04
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 SellCompany -35,769 0.0313%
8/31/26 SellCompany -78,145 0.0685%
3/2/26 Free

Director

50,000 0.0439%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+0.64%-9.54%-20.68% 357M
-1.16%-3.97%-2.91%+13.00% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.05%+12.16%+29.80% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.86%+0.50%+64.32%+95.17% 27.54B
Weighted average by Cap. -0.99%+0.05%+88.82%+128.22%

Financials

2026 *2027 *
Net sales 335K 289K 271K 248K 463K 31.69M 465K 3.22M 1.24M 16.24M 1.26M 1.23M 51.71M 396K 341K 321K 293K 547K 37.43M 549K 3.8M 1.47M 19.18M 1.49M 1.46M 61.07M
Net income -116M -99.42M -93.52M -85.34M -160M -10.92B -160M -1.11B -428M -5.6B -434M -424M -17.82B -135M -116M -109M -99.88M -187M -12.78B -187M -1.3B -501M -6.55B -508M -497M -20.85B
Net Debt -167M -143M -135M -123M -230M -15.73B -231M -1.6B -617M -8.06B -625M -612M -25.67B -231M -199M -187M -170M -319M -21.81B -320M -2.21B -855M -11.18B -867M -848M -35.59B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
26-09-04 US$3.130 +0.32% 1,365,189
26-09-03 US$3.120 +0.65% 931,703
26-09-02 US$3.100 0.00% 864,638
26-09-01 US$3.100 -1.90% 705,838
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
3.130USD
Average target price
12.29USD
Spread / Average Target
+292.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!